GGrantIndex
Sort

23,748 grants matching melanoma

CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY

$737,794
Michael I Nishimura · Loyola University Chicago · P01 · FY2014 · CA

Senior Leaders

$737,786
Judith Cheryl Gasson · University Of California Los Angeles · P30 · FY2009 · CA

3D Bioprinted skin models for drug screening

$737,751
Marc Ferrer-Alegre · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR

Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade

$737,605
Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2018 · CA

Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma

$737,540
John W Babich · Molecular Insight Pharmaceuticals, Inc. · R44 · FY2011 · CA

Regulation of Lymphocyte Proliferation and Replicative Capacity

$737,535
Richard J. Hodes · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Processed Antigen Characterization by Mass Spectrometry

$737,483
Donald F Hunt · University Of Virginia · R01 · FY2009 · AI

Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling

$737,149
Mark A. Lemmon · Yale University · R01 · FY2020 · CA

GCDH Addiction in Melanoma

$736,400
Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA

Tissue Array Research Program

$736,349
Stephen Hewitt · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA

A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors

$735,428
Song Yao · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA

Personalized Genomic Testing for Melanoma: Maximizing Personal Utility and Reach

$735,067
Jennifer L Hay · Sloan-Kettering Inst Can Research · R01 · FY2014 · CA

CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY

$735,043
Michael I Nishimura · Loyola University Chicago · P01 · FY2013 · CA

Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation

$734,862
Katerina Abigail Politi · Yale University · R01 · FY2019 · CA

Development of Virtual Tumor

$734,822
Thomas S Deisboeck · Massachusetts General Hospital · U56 · FY2006 · CA

Genetic Epidemiology

$734,639
Alisa Goldstein · Division Of Cancer Epidemiology And Genetics · ZIA · FY2019 · CA

Mechanisms of racial disparity in breast cancer-related lymphedema

$734,550
Babak J Mehrara · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Mechanisms of racial disparity in breast cancer-related lymphedema

$734,550
Babak J Mehrara · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Molecular Diagnostics Core Laboratory

$734,451
Mark Raffeld · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA

The COVID-19 and Cancer Consortium (CCC19) Registry

$732,687
Jeremy Lyle Warner · Rhode Island Hospital · U01 · FY2024 · CA

LKB1 tumor suppressor and human cancer

$732,590
Diego H Castrillon · Ut Southwestern Medical Center · U01 · FY2013 · CA

Biomechanics Of Cochlear Fine Tuning

$732,420
Richard S. Chadwick · National Institute On Deafness And Other Communication Disorders · ZIA · FY2015 · DC

Illinois Oncology Research Association Community Clinical Oncology Program

$732,293
Nguyet A. Le-Lindqwister · Oncology-Hematology Assoc-Central Ill · U10 · FY2011 · CA

In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study

$732,170
Andres Mario Salazar · Oncovir, Inc. · R44 · FY2017 · CA

In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study

$732,170
Andres Mario Salazar · Oncovir, Inc. · R44 · FY2016 · CA